Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
AVDL

AVDL - Avadel Pharmaceuticals PLC Stock Price, Fair Value and News

$21.64 
Market Closed

23/100

AVDL

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

23/100

AVDL

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

AVDL Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

AVDL Price Action

Last 7 days

-0.2%

Last 30 days

0.7%

Last 90 days

-8.1%

Trailing 12 Months

140.7%

AVDL RSI Chart

AVDL Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

AVDL Valuation

Market Cap

2.1B

Price/Earnings (Trailing)

-7.6K

Price/Sales (Trailing)

8.5

EV/EBITDA

200.73

Price/Free Cashflow

53.46

AVDL Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

AVDL Fundamentals

AVDL Revenue

Revenue (TTM)

248.5M

Rev. Growth (Yr)

54.86%

Rev. Growth (Qtr)

13.71%

AVDL Earnings

Earnings (TTM)

-278.0K

Earnings Growth (Yr)

100.76%

Earnings Growth (Qtr)

-99.79%

AVDL Profitability

EBT Margin

-1.31%

Return on Equity

-0.28%

Return on Assets

-0.14%

Free Cashflow Yield

1.87%

AVDL Investor Care

Shares Dilution (1Y)

1.34%

Diluted EPS (TTM)

0.01

AVDL Alerts

  • 1 major insider sales recently.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2025194.4M221.1M248.5M0
202455.0M95.1M138.1M169.1M
20231.6M2.3M9.2M28.1M
202201.9M1.9M0
202117.3M12.3M7.3M2.3M
202055.0M47.6M33.3M22.3M
201986.4M74.7M69.1M59.2M
2018154.4M136.6M116.7M103.3M
2017166.2M175.1M182.7M173.6M
2016176.6M166.2M150.9M149.9M
201554.5M94.0M133.6M173.1M
20146.9M9.6M12.3M15.0M
20136.7M5.9M5.0M4.2M
201226.3M20.1M13.8M7.5M
201135.6M34.1M032.6M
201000037.1M
200900042.1M
Get all data in R, Python etc through our Historical Stock Data APIs

About Avadel Pharmaceuticals PLC

AVDL
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
 CEO
 WEBSITEavadel.com
 SECTORHealthcare
 INDUSTRYDrug Manufacturers Specialty & Generic
 EMPLOYEES41

Avadel Pharmaceuticals PLC Frequently Asked Questions

AVDL is the stock ticker symbol of Avadel Pharmaceuticals PLC. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Feb 13 2026, market cap of Avadel Pharmaceuticals PLC is 2.11 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Feb 13 2026, AVDL's PE ratio (Price to Earnings) is -7601.76 and Price to Sales (PS) ratio is 8.5. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AVDL PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Avadel Pharmaceuticals PLC has provided 0.087 (multiply by 100 for percentage) rate of return.